Molecular Biology Reports

, Volume 38, Issue 5, pp 3001–3011 | Cite as

α-Dystrobrevin distribution and association with other proteins in human promyelocytic NB4 cells treated for granulocytic differentiation

  • V. V. BorutinskaiteEmail author
  • K.-E. Magnusson
  • R. Navakauskiene


Dystrobrevins (DBs) bind directly to dystrophin and are prominent components of the dystrophin-associated protein complex (DAPC) that links the cytoskeleton to the extracellular matrix. They are involved in brain development, synapse formation and plasticity, as well as water and ion homeostasis. However, the role of DB in non-muscular cells is not clear. In this study, we show that different α-dystrobrevin isoforms are present in promyelocytic leukemia (NB4) cells. Only the biggest α-dystrobrevin isoform (DB-α), which can be important for its function, was expressed in the membrane fraction of NB4 cells; the other α-DB isoforms were found in the hydrophilic cell fractions. Employing the immunoprecipitation and mass spectrometry, we identified novel α-DB-interacting proteins involved in cytoskeleton reorganization (actin, tropomyosin, gelsolin, tubulin) and signal transduction process (stathmin, prohibitin, RIBA) during proliferation and differentiation of NB4 cells. Our results suggest that α-DB isoforms play a central role in cytoskeleton reorganization via their multiple interactions with actin and actin-associating proteins and may participate in signal transduction process during NB4 cell granulocytic differentiation via directly and non directly associated proteins.


α-dystrobrevin Histone deacetylase inhibitor BML-210 Retinoic acid Granulocytic differentiation 





All-trans retinoic acid


Histone deacetylase inhibitor



This research was supported by the Swedish Institute (Visby Program No. 00879/2009), the Swedish Research Council, Lithuanian State Science and Studies Foundation (No.V-12/2009) and EU Marie Curie Programme Fellowship for V.V. Borutinskaite.


  1. 1.
    Rando TA (2001) The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24:1575–1594PubMedCrossRefGoogle Scholar
  2. 2.
    Dalkilic I, Kunkel LM (2003) Muscular dystrophies: genes to pathogenesis. Curr Opin Genet Dev 13:231–238PubMedCrossRefGoogle Scholar
  3. 3.
    Grady RM, Grange RW, Lau KS, Maimone MM, Nichol MC, Stull JT, Sanes JR (1999) Role for α-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1:215–220PubMedCrossRefGoogle Scholar
  4. 4.
    Albrecht DE, Froehner SC (2004) DAMAGE, a novel α-dystrobrevin-associated MAGE protein in dystrophin complexes. J Biol Chem 279(8):7014–7023PubMedCrossRefGoogle Scholar
  5. 5.
    Yoshida M, Hama H, Ishikawa-Sakurai M, Imamura M, Mizuno Y, Araishi K, Wakabayashi-Takai E, Noguchi S, Sasaoka T, Ozawa E (2000) Biochemical evidence for association of dystrobrevin with the sarcoglycan–sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet 9:1033–1040PubMedCrossRefGoogle Scholar
  6. 6.
    Mizuno Y, Thompson TG, Guyon RJ, Lidov HGW, Brosius M, Imamura M, Ozawa E, Watkins SC, Kunkel LM (2001) Desmuslin, an intermediate filament protein that interacts with α-dystrobrevin and desmin. PNAS 98(11):6156–6161PubMedCrossRefGoogle Scholar
  7. 7.
    Newey SE, Howman EV, Ponting CP, Benson AM, Nawrotzki R, Loh NY, Davies KE, Blake DJ (2001) Syncoilin, a novel member of the intermediate filament superfamily that interacts with a-dystrobrevin in skeletal muscle. J Biol Chem 276:6645–6655PubMedCrossRefGoogle Scholar
  8. 8.
    Costa ML, Escaleira R, Cataldo A, Oliveira F, Mermelstein CS (2004) Desmin: molecular interactions and putative functions of the muscle intermediate filament protein. Braz J Med Biol Res 37(12):1819–1830PubMedCrossRefGoogle Scholar
  9. 9.
    Ceccarini M, Torreri P, Lombardi DG, Macchia G, Macioce P, Petrucci TC (2005) Molecular basis of dystrobrevin interaction with kinesin heavy chain: structural determinants of their binding. J Mol Biol 354:872–882PubMedCrossRefGoogle Scholar
  10. 10.
    Fuentes-Mera L, Rodríguez-Muñoz R, González-Ramírez R, García-Sierra F, González E, Mornet D, Cisneros B (2006) Characterization of a novel Dp71 dystrophin-associated protein complex (DAPC) present in the nucleus of HeLa cells: members of the nuclear DAPC associate with the nuclear matrix. Exp Cell Res 312:3023–3035PubMedCrossRefGoogle Scholar
  11. 11.
    Kulyte A, Navakauskiene R, Treigyte G, Gineitis A, Bergman T, Magnusson KE (2002) Characterization of human alpha-dystrobrevin isoforms in HL-60 human promyelocytic leukemia cells undergoing granulocytic differentiation. Mol Biol Cell 13(12):4195–4205PubMedCrossRefGoogle Scholar
  12. 12.
    Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, Navakauskiene R (2006) The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol 549(1–3):9–18PubMedCrossRefGoogle Scholar
  13. 13.
    Chen Z, Wang W, Pan J, Chen L, Xue Y (1999) Combination of all-trans-retinoic acid with butyric acid and its prodrugs markedly enhancing differentiation of human acute promyelocytic leukemia NB4 cells. Chin Med J Engl 112:352–355PubMedGoogle Scholar
  14. 14.
    Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans-retinoic acid. Cancer Res 61:3591–3594PubMedGoogle Scholar
  15. 15.
    Demary K, Wong L, Spanjard RA (2001) Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 163:103–107PubMedCrossRefGoogle Scholar
  16. 16.
    Waleryck D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, King FW, Helwak A, Boros J, Zylicz A, Zylicz M (2004) Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 279(47):48836–48845CrossRefGoogle Scholar
  17. 17.
    Boyum A (1968) A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field. Scand J Clin Lab Investig 97:51–76Google Scholar
  18. 18.
    Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68:850–858PubMedCrossRefGoogle Scholar
  19. 19.
    Shevchenko A, Chernushevic I, Wilm M, Mann M (2002) ‘De novo’ sequencing of peptides recovered from in-gel digested proteins by nanoelectrospray tandem mass spectrometry. Mol Biotechnol 20:107–118PubMedCrossRefGoogle Scholar
  20. 20.
    Nawrotzki R, Loh NY, Ruegg MA, Davies KE, Blake DJ (1998) Characterisation of alpha-dystrobrevin in muscle. J Cell Sci 111:2595–2605PubMedGoogle Scholar
  21. 21.
    Sadoulet-Puccio HM, Khurana TS, Cohen JB, Kunkel LM (1996) Cloning and characterization of the human homologue of a dystrophin related phosphoprotein found at the Torpedo electric organ post-synaptic membrane. Hum Mol Genet 5:489–496PubMedCrossRefGoogle Scholar
  22. 22.
    Haenggi T, Fritschy JM (2006) Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue. Cell Mol Life Sci 63:1614–1631PubMedCrossRefGoogle Scholar
  23. 23.
    Lien CF, Hazai D, Yeung D, Tan J, Fuchtbauer EM, Jancsik V, Gorecki DC (2006) Expression of α-dystrobrevin in blood-tissue barriers: sub-cellular localisation and molecular characterisation in normal and dystrophic mice. Cell Tissue Res 327(1):67–82PubMedCrossRefGoogle Scholar
  24. 24.
    Grady RM, Akaaboune M, Cohen AL, Maimore MM, Lichtman JW, Sanes JR (2003) Tyrosine-phosphorylated and nonphosphorylated isoforms of α-dystrobrevin: roles in skeletal muscle and its neuromuscular and myotendious junction. J Cell Biol 160(5):741–752PubMedCrossRefGoogle Scholar
  25. 25.
    Ahn JS, Jang IS, Rhim JH, Kim K, Yeo EJ, Park SC (2003) Gelsolin for senescence associated resistance to apoptosis. Ann N Y Acad Sci 1010:493–495PubMedCrossRefGoogle Scholar
  26. 26.
    Mishra S, Murphy LC, Murphy LJ (2006) The prohibitins: emerging roles in diverse functions. J Cell Mol Med 10(2):353–363PubMedCrossRefGoogle Scholar
  27. 27.
    Pratt WB (1997) The role of the Hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signalling via MAP kineses. Ann Rev Pharmacol Toxicol 37:297–326CrossRefGoogle Scholar
  28. 28.
    Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM (1996) Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signaling pathway. Mol Cell Biol 16:5839–5845PubMedGoogle Scholar
  29. 29.
    Srethapakdi M, Liu F, Tavorath R, Rosen N (2000) Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 60:3940–3946PubMedGoogle Scholar
  30. 30.
    Roberts RG (2001) Dystrophins and dystrobrevins. Genome Biol 2(4):reviews3006.1–reviews3006.7Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • V. V. Borutinskaite
    • 2
    • 1
    Email author
  • K.-E. Magnusson
    • 1
  • R. Navakauskiene
    • 2
  1. 1.Division of Medical Microbiology, Department of Clinical and Experimental MedicineLinköping UniversityLinkopingSweden
  2. 2.Department of Developmental BiologyInstitute of BiochemistryVilniusLithuania

Personalised recommendations